- Home
- CMMB vs IBG Comparison
CMMB vs IBG Comparison
Compare CMMB & IBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMMB | IBG |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | Israel | Australia |
| Employees | N/A | 9 |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 2.5M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | CMMB | IBG |
|---|---|---|
| Price | $2.06 | $1.01 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | 71.3K | ★ 625.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $52.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.30 |
| 52 Week High | $3.86 | $6.50 |
Technical Indicators
Market Signals| Indicator | CMMB | IBG |
|---|---|---|
| Relative Strength Index (RSI) | 60.58 | 32.96 |
| Support Level | $1.48 | $0.51 |
| Resistance Level | $2.24 | $1.75 |
| Average True Range (ATR) | 0.21 | 0.58 |
| MACD | 0.03 | -0.42 |
| Stochastic Oscillator | 79.92 | 1.25 |
Price Performance
Historical ComparisonAbout CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.